Literature DB >> 19141538

The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking.

Fiona C Kimberley1, Liesbeth van Bostelen, Katherine Cameron, Gijs Hardenberg, J Arnoud Marquart, Michael Hahne, Jan Paul Medema.   

Abstract

A proliferation-inducing ligand (APRIL) (also known as TALL-2 and TRDL-1) is a member of the tumor necrosis factor (TNF) superfamily that has tumorigenic properties but is also important for the induction of humoral immune responses. APRIL binds two TNF receptors: transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and B-cell maturation antigen (BCMA) as well as heparan sulfate proteoglycans (HSPGs). The aim of this study was to clarify the role of the HSPG interaction in canonical APRIL signaling, because it has been proposed to act as a docking site and also to play a role in direct signaling. In this study, we generated point mutants of soluble APRIL that lack either the capacity to bind HSPGs or TACI and BCMA and then tested the function of these mutants in mouse B-cell assays. In contrast to previous reports, we found that APRIL alone is sufficient to costimulate B-cell proliferation and drive IgA production and does not require artificial antibody cross-linking. We found no evidence that APRIL requires signaling through HSPGs but, notably, were able to show that binding of APRIL to HSPGs is crucial for mediating natural APRIL cross-linking to allow for optimal activation of murine B cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141538     DOI: 10.1096/fj.08-124669

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  31 in total

1.  Virally-induced upregulation of heparan sulfate on B cells via the action of type I IFN.

Authors:  Nadine Jarousse; Damian L Trujillo; Sarah Wilcox-Adelman; Laurent Coscoy
Journal:  J Immunol       Date:  2011-11-02       Impact factor: 5.422

2.  Isolation and functional analysis of syndecans.

Authors:  Pyong Woo Park
Journal:  Methods Cell Biol       Date:  2017-10-06       Impact factor: 1.441

3.  TNF superfamily member 13, APRIL, inhibits allergic lung inflammation.

Authors:  Yanping Xiao; Seiichi Motomura; Vadim Deyev; Eckhard R Podack
Journal:  Eur J Immunol       Date:  2010-12-01       Impact factor: 5.532

Review 4.  Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Authors:  Robert C Rickert; Julia Jellusova; Ana V Miletic
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 5.  New roles for the BLyS/BAFF family in antigen-experienced B cell niches.

Authors:  Radhika Goenka; Jean L Scholz; Vishal J Sindhava; Michael P Cancro
Journal:  Cytokine Growth Factor Rev       Date:  2014-01-10       Impact factor: 7.638

Review 6.  The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies.

Authors:  David Wallach
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-10-01       Impact factor: 10.005

Review 7.  The function of BAFF on T helper cells in autoimmunity.

Authors:  Maogen Chen; Xiaohong Lin; Ya Liu; Qiang Li; Yiling Deng; Zhongmin Liu; David Brand; Zhiyong Guo; Xiaoshun He; Bernhard Ryffel; Song Guo Zheng
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-24       Impact factor: 7.638

Review 8.  The Role of BAFF System Molecules in Host Response to Pathogens.

Authors:  Jiro Sakai; Mustafa Akkoyunlu
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

9.  The design and characterization of receptor-selective APRIL variants.

Authors:  Fiona C Kimberley; Almer M van der Sloot; Marco Guadagnoli; Katherine Cameron; Pascal Schneider; J Arnoud Marquart; Miranda Versloot; Luis Serrano; Jan Paul Medema
Journal:  J Biol Chem       Date:  2012-09-07       Impact factor: 5.157

10.  Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.

Authors:  T Matthes; T McKee; I Dunand-Sauthier; B Manfroi; S Park; J Passweg; B Huard
Journal:  Leukemia       Date:  2015-03-10       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.